Eplerenone treatment improved memory and reduced AChE activity and neuroinflammation in an STZ-induced Alzheimer’s model, indicating potential cognitive protection through MR antagonism in Alzheimer’s disease models. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.